Kaleido Biosciences Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Kaleido Biosciences last-minute Real Value cannot be determined due to lack of data. The latest price of Kaleido Biosciences is $0.0. Our model forecasts the value of Kaleido Biosciences from analyzing the firm fundamentals such as Return On Equity of -5.81, operating margin of (79.28) %, and Shares Outstanding of 42.62 M as well as examining its technical indicators and probability of bankruptcy.
Kaleido Biosciences Total Value Analysis
Kaleido Biosciences is now forecasted to have valuation of (16.73 M) with market capitalization of 421.96 K, debt of 5.55 M, and cash on hands of 38.47 M. The negative valuation of Kaleido Biosciences may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Kaleido Biosciences fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(16.73 M) | 421.96 K | 5.55 M | 38.47 M |
Kaleido Biosciences Investor Information
The company has price-to-book ratio of 0.0. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kaleido Biosciences recorded a loss per share of 2.16. The entity had not issued any dividends in recent years. Based on the key indicators related to Kaleido Biosciences' liquidity, profitability, solvency, and operating efficiency, Kaleido Biosciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Kaleido Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kaleido Biosciences has an asset utilization ratio of 2.2 percent. This suggests that the Company is making $0.022 for each dollar of assets. An increasing asset utilization means that Kaleido Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Kaleido Biosciences Ownership Allocation
Kaleido Biosciences maintains a total of 42.62 Million outstanding shares. Roughly 98.91 % of Kaleido Biosciences outstanding shares are held by general public with 0.73 pct. owned by insiders and only 0.36 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kaleido Biosciences Profitability Analysis
The company reported the previous year's revenue of 1.1 M. Net Loss for the year was (90.29 M) with loss before overhead, payroll, taxes, and interest of (66.7 M).Kaleido Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 33.5 M | |
| Retained Earnings | -364.5 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |